Chen, Yuan-Tsong

Distinguished Research Fellow / Institute of Biomedical Sciences, Academia Sinica

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-27899104


  • 1976 - 1978 Ph.D., Human Genetics, New York , Columbia University
  • 1992 - 1998 Director, Medical Genetics Fellowship Training Program, Duke University Medical Center, Durham, NC
  • 1993 - present Professor, Department of Pediatrics, Duke University Medical Center, Durham, NC
  • 1994 - present Chief, Division of Medical Genetics, Duke University Medical Center, Durham, NC
  • 1995 - present Professor, Department of Genetics, Duke University Medical Center, Durham, NC
  • 2001 - present Director, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan


  • 1983-1985 Charles E. Culpepper Fellow
  • 1992-2001 The Best Doctors in America
  • 2000 J.C. Pompe Award (First recipient), Children's Pompe Foundation
  • 2001 Alpha Omega Alpha Honor Medical Society, elected faculty
  • 2001 Distinguished Research Fellow, Academia Sinica
  • 2002 Academician, Academia Sinica
  • 2002 Foreign Scientific Advisor, Japanese Scoiety of Lysosomal Storage Disorders


Our overall research interests are in translational research. We aim at translating the promise of genomic medicine into clinical reality.

Specific projects at present time include:

  1. Chen_Yuan-Tsong_pic01Identification of novel genes/targets associated with human diseases. Genetic epidemiology, mouse ENU mutagenesis, bioinformatics, bioinformatics and proteomics are some approaches that we use in identification of novel genes associated with the human disease. Genes for several monogenic diseases have been mapped and/or identified or identified. Genetic markers associated with drug-induced Stevens-Johnson syndrome have been identified. Using ENU mutagenesis we have identified a mouse model resembling human maple syrup urine disease.
  2. Functional characterization of a novel glucose transporter and its role in diabetes mellitus.
  3. Enzyme and gene therapy and targeting mechanisms of Pompe disease.